Tumor oxygenation correlates with molecular growth determinants in breast cancer

被引:57
作者
Hohenberger, P
Felgner, C
Haensch, W
Schlag, PM
机构
[1] Humboldt Univ, Virchow Hosp, Max Delbruck Ctr Mol Med, Tumor Inst, D-13122 Berlin, Germany
[2] Humboldt Univ, Robert Rossle Hosp, Div Surg & Surg Oncol, D-13122 Berlin, Germany
关键词
breast cancer; oxygen partial pressure; molecular markers; prognostic factors;
D O I
10.1023/A:1005921513083
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hypoxic tumor cells may represent a fraction of cells that are not susceptible to radiation or chemotherapy. Intratumoral oxygen partial pressure (pO(2)) is the result of oxygen delivery and consumption. Cell proliferation is one factor to effect oxygen consumption and we therefore studied the correlation between tumor pO(2) and histological parameters. Patients and methods: In 36 women and one man (age range 29-80 years) with suspected breast cancer. Before tumor resection, intralesional pO(2) was determined with a polarographic needle electrode. Under ultrasound control, 200 tumor measurements were obtained; Hb levels, Hk, arterial blood gas parameters, and tissue temperature were determined. The median of pO(2) values and the percentage of hypoxic areas (pO(2) < 10 mmHg) were calculated and correlated with the histological type, grading, ER, PR, and the expression of Ki-67, p53, EGFR, pS2, and c-erb-B2. Results: The overall median pO(2) was 44 mmHg, and 1024 measurements (13.8%) represented hypoxic areas. Ductal and lobular invasive cancers showed median pO(2) of 41 mmHg. The mean pO(2) of G1 tumors was 59 mmHg and the hypoxic fraction 8%, in contrast to G2 tumors with 43 mmHg and 17%, and G3 tumors with 36 mmHg and 20.4% (p < 0.01). We observed a correlation with tumor size and an increased rate of hypoxic areas in T3-4 lesions (p < 0.02). Also tumors with negative nodes or positive ER had significantly higher pO(2) values, as did tumors with an overexpression of c-erb-B2, p53, and cathepsin D. Conclusion: Oxygenation of human breast cancers can safely be measured in patients prior to surgical therapy, pO(2) values correlate both with prognostic markers examined histologically and with molecular growth factors. As the efficacy of preoperative or adjuvant treatment in individuals may depend on oxygen partial pressure, efforts to manipulate tumor pO(2) for therapeutic purpose could be promising.
引用
收藏
页码:97 / 106
页数:10
相关论文
共 43 条
[1]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[2]   PROGNOSTIC VALUE OF INTRATUMORAL MICROVESSEL DENSITY, A MEASURE OF TUMOR ANGIOGENESIS, IN NODE-NEGATIVE BREAST-CARCINOMA - RESULTS OF A MULTIPARAMETRIC STUDY [J].
BEVILACQUA, P ;
BARBARESCHI, M ;
VERDERIO, P ;
BORACCHI, P ;
CAFFO, O ;
DALLAPALMA, P ;
MELI, S ;
WEIDNER, N ;
GASPARINI, G .
BREAST CANCER RESEARCH AND TREATMENT, 1995, 36 (02) :205-217
[3]  
BOUCHER Y, 1990, CANCER RES, V50, P4478
[4]  
BRIOZZO P, 1988, CANCER RES, V48, P3688
[5]  
Brizel DM, 1996, CANCER RES, V56, P941
[6]   IMMUNOENZYMATIC LABELING OF MONOCLONAL-ANTIBODIES USING IMMUNE-COMPLEXES OF ALKALINE-PHOSPHATASE AND MONOCLONAL ANTI-ALKALINE PHOSPHATASE (APAAP COMPLEXES) [J].
CORDELL, JL ;
FALINI, B ;
ERBER, WN ;
GHOSH, AK ;
ABDULAZIZ, Z ;
MACDONALD, S ;
PULFORD, KAF ;
STEIN, H ;
MASON, DY .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1984, 32 (02) :219-229
[7]   THE P53 TUMOR-SUPPRESSOR GENE IN BREAST-CANCER [J].
ELLEDGE, RM ;
ALLRED, DC .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 32 (01) :39-47
[8]  
FITZPATRICK SL, 1984, CANCER RES, V44, P3448
[9]   PROGNOSTIC VALUE OF PS2 AND CATHEPSIN-D IN 710 HUMAN PRIMARY BREAST-TUMORS - MULTIVARIATE-ANALYSIS [J].
FOEKENS, JA ;
VANPUTTEN, WLJ ;
PORTENGEN, H ;
DEKONING, HYWCM ;
THIRION, B ;
ALEXIEVAFIGUSCH, J ;
KLIJN, JGM .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (05) :899-908
[10]   RELATIONSHIP OF PS2 WITH RESPONSE TO TAMOXIFEN THERAPY IN PATIENTS WITH RECURRENT BREAST-CANCER [J].
FOEKENS, JA ;
PORTENGEN, H ;
LOOK, MP ;
VANPUTTEN, WLJ ;
THIRION, B ;
BONTENBAL, M ;
KLIJN, JGM .
BRITISH JOURNAL OF CANCER, 1994, 70 (06) :1217-1223